Glucose (DrugBank: Glucose)
15 diseases| 告示番号 | 疾患名（ページ内リンク） | 臨床試験数 |
|---|---|---|
| 2 | 筋萎縮性側索硬化症 | 1 |
| 6 | パーキンソン病 | 2 |
| 13 | 多発性硬化症／視神経脊髄炎 | 2 |
| 49 | 全身性エリテマトーデス | 3 |
| 50 | 皮膚筋炎／多発性筋炎 | 1 |
| 65 | 原発性免疫不全症候群 | 2 |
| 75 | クッシング病 | 1 |
| 86 | 肺動脈性肺高血圧症 | 2 |
| 88 | 慢性血栓塞栓性肺高血圧症 | 1 |
| 96 | クローン病 | 1 |
| 160 | 先天性魚鱗癬 | 1 |
| 195 | ヌーナン症候群 | 1 |
| 254 | ポルフィリン症 | 1 |
| 257 | 肝型糖原病 | 2 |
| 299 | 嚢胞性線維症 | 35 |
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | NCT03039673 (ClinicalTrials.gov) | June 19, 2017 | 31/1/2017 | MIROCALS: Modifying Immune Response and OutComes in ALS | Efficacy and Safety of Low-dose IL-2 (Ld-IL-2) as a Treg Enhancer for Controlling Neuro-inflammation in Newly Diagnosed Amyotrophic Lateral Sclerosis (ALS) Patients: A Randomized, Double-blind, Placebo- Controlled, Phase-II Proof of Concept/ Proof of Mechanism Clinical Trial | Amyotrophic Lateral Sclerosis | Drug: Riluzole;Drug: IL-2;Drug: 5% glucose water solution | Centre Hospitalier Universitaire de Nimes | NULL | Active, not recruiting | 18 Years | 75 Years | All | 304 | Phase 2 | France;United Kingdom |
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | JPRN-jRCTs051180214 | 29/03/2019 | 27/03/2019 | The usefulness of flutemetamol for diagnostic imaging of neurogenerative disease | The usefulness of brain amyloid image using flutemetamol and glucose metabolism for the neurogenerative disease - The usefulness of brain amyloid image using flutemetamol and glucose metabolism for the neurogenerative disease | Alzheimer's disease,Dementia with Lewy Bodies,Parkinson's syndrome,Frontotemporal lober degeneration Alzheimer's disease, Dementia with Lewy Bodies, Parkinson's syndrome, Frontotemporal lober degeneration, Parkinson's disease, Mild cognitive impairment, Non-Alzheimer's disease, Progressive aphasia, Neurodegenerative disease, Cerebral corticobasal degeneration, Progressive supranuclear palsy | Amyloid PET: Given the flutemetamol (3mL) intravenously FDG-PET:Given the FDG scanR (3mL) intravenously | Itoh Yoshiaki | NULL | Recruiting | Ages 20 and over | N/A | Both | 100 | N/A | Japan |
| 2 | NCT00004451 (ClinicalTrials.gov) | March 1998 | 18/10/1999 | Randomized Study of the Effects of Glucose on Cognition in Healthy Young and Elderly People and Parkinson's Disease Patients | Parkinson Disease | Drug: Glucose | National Institute of Mental Health (NIMH) | University of Virginia | Completed | 18 Years | N/A | Both | 120 | N/A | United States |
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | NCT03052595 (ClinicalTrials.gov) | February 1, 2017 | 10/2/2017 | Multiple Sclerosis: The Role of Mitochondrial Dysfunction in IR Resistance | Multiple Sclerosis: The Role of Mitochondrial Dysfunction in Insulin Resistance | Multiple Sclerosis;Mitochondrial Alteration | Diagnostic Test: Oral glucose tolerance test;Diagnostic Test: Testing of autonomous nervous system function;Diagnostic Test: Stroop test | Slovak Academy of Sciences | Comenius University | Recruiting | 18 Years | 45 Years | All | 70 | Slovakia | |
| 2 | NCT00062972 (ClinicalTrials.gov) | September 1999 | 18/6/2003 | Improving Memory in Patients With Multiple Sclerosis | Interventions to Improve Memory in Patients With Multiple Sclerosis | Multiple Sclerosis | Drug: donepezil;Drug: glucose | Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) | U.S. Department of Education | Withdrawn | 18 Years | 56 Years | All | 0 | Phase 3 | United States |
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | ChiCTR1800015030 | 2018-03-01 | 2018-03-01 | A Clinical Trial on Safety and effect of Dapagliflozin to Control Blood Glucose Levels in Systemic Lupus Erythematosus | The Safety of SGLT2-i Dapagliflozin on Treating Blood Glucose Levels in SLE | Systemic Lupus Erythematosus | Case series:add-on or replace dapagliflozin; | Dept. Rheumatology, Renji Hospital South Campus | NULL | Pending | 18 | 70 | Both | Case series:35; | 4 (Phase 4 study) | China |
| 2 | NCT03296995 (ClinicalTrials.gov) | July 1, 2017 | 25/9/2017 | Accuracy, Feasibility and Acceptance of CGM Lupus | Accuracy, Feasibility and Acceptance of Continuous Glucose Monitoring in Critically Systemic Lupus Erythematosus | Systemic Lupus Erythematosus;Critical Illness;Diabetic Blood Glucose Monitoring | Device: Flash glucose monitoring system | RenJi Hospital | NULL | Recruiting | 18 Years | N/A | All | 30 | N/A | China |
| 3 | NCT00029926 (ClinicalTrials.gov) | January 2002 | 26/1/2002 | Positron Emission Tomography (PET) to Locate Areas of White Blood Cell Activity | A Pilot Study of F-18FDG Positron Emission Tomography (PET) to Assess the Distribution of Activated Lymphocytes in Systemic Lupus Erythematosus (SLE) | Lupus Erythematosus;Systemic | Drug: 2-deoxy-2 [F-18] fluoro-2-d-glucose | National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) | NULL | Completed | N/A | N/A | Both | 20 | N/A | United States |
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | NCT02267005 (ClinicalTrials.gov) | March 2015 | 1/10/2014 | The Effect of Creatine Supplementation on Muscle Function in Childhood Myositis | The Effect of Creatine Supplementation on Muscle Function in Childhood Myositis | Juvenile Dermatomyositis | Dietary Supplement: Creapure;Dietary Supplement: Glucose Tablet | The Hospital for Sick Children | NULL | Completed | 7 Years | 18 Years | All | 13 | N/A | Canada |
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | NCT04275479 (ClinicalTrials.gov) | January 10, 2020 | 10/2/2020 | Diabetes/ Endocrine Surveillance in SDS | Endocrine Diabetes Screening in Patients With Shwachman-Diamond Syndrome DIABETES/ ENDOCRINE SURVEILLANCE IN SDS | Shwachman-Diamond Syndrome | Diagnostic Test: Oral Glucose Tolerance Test;Other: Modified Oral Glucose Tolerance Test;Other: Modified Mixed Meal Tolerance Test;Device: Continuous Glucose Monitor;Other: Food Diary;Other: Medical History Questionnaires | Washington University School of Medicine | Shwachman Diamond Syndrome Foundation;Barnes-Jewish Hospital | Recruiting | 3 Years | N/A | All | 60 | United States | |
| 2 | EUCTR2018-004191-35-BE (EUCTR) | 12/04/2019 | 05/03/2019 | Use of an antidiabetic drug (Empagliflozin) to lower the blood level of 1,5-anhydroglucitol in patients deficient in the glucose-6-phosphate transporter (GSD1b) and the phosphatase G6PC3, both of the endoplasmic reticulum, to treat their recurrent infections by normalizing their blood neutrophil counts. Neutrophils are the most abundant white blood cells in our blood that are essential to help fighting infections. 1,5-anhydroglucitol is a sugar derivative with no known function. | Evaluation of the safety and efficacy of administration of Empagliflozin in a new treatment for neutropenia in patients with Glycogen Storage Disease type 1b (GSD1b) and G6PC3 deficiency. - GLYCO-1B | (1) Severe Congenital Neutropenia type 4 (SNC4) due to a deficiency in G6PC3, a phosphatase of the endoplasmic also known a Ubiquitous glucose-6-phosphatase and (2) the neutropenia in Glycogen Storage Disease type 1b due to a deficiency in the glucose-6-phosphate transporter (G6PT / SLC37A4) of the endoplasmic reticulum.;Therapeutic area: Diseases [C] - Nutritional and Metabolic Diseases [C18] | Trade Name: Jardiance Product Name: Empagliflozin Product Code: A10BK03 | Cliniques universitaires Saint-Luc | NULL | Authorised-recruitment may be ongoing or finished | Female: yes Male: yes | 5 | Phase 4 | Belgium |
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | NCT02574793 (ClinicalTrials.gov) | December 1, 2014 | 9/10/2015 | Glycemic Fluctuations in Newly Diagnosed Growth Hormone-Secreting Pituitary Adenoma and Cushing Syndrome Subjects | Characteristics of Glycemic Fluctuations in Newly Diagnosed Growth Hormone-Secreting Pituitary Adenoma and Cushing Syndrome Subjects | Pituitary Adenoma | Device: continuous glucose monitoring | Huashan Hospital | NULL | Completed | N/A | N/A | All | 60 | China |
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | NCT01953965 (ClinicalTrials.gov) | September 2013 | 26/9/2013 | Look at Way the Heart Functions in People With Pulmonary Hypertension (PH) Who Have Near Normal Right Ventricle (RV) Function and People With Pulmonary Hypertension Who Have Impaired RV Function. Using Imaging Studies PET Scan and Cardiac MRI. | 11C-acetate/18Fluorodeoxyglucose-FDG PET/Cardiac MRI in Pulmonary Hypertension | Pulmonary Arterial Hypertension;Chronic Thromboembolic Pulmonary Hypertension | Drug: 11C-acetate;Drug: [18F]Fluoro-2-deoxy-2-D-glucose;Drug: MultiHance | Brigham and Women's Hospital | University of Pennsylvania;University of Maryland;Yale University | Terminated | 18 Years | 72 Years | Both | 4 | Phase 2 | United States |
| 2 | NCT01637675 (ClinicalTrials.gov) | May 2013 | 1/7/2012 | Efficacy and Safety Study of Sodium Tanshinone IIA Sulfonate on Pulmonary Hypertension | Clinical Study of Effects of Sodium Tanshinone IIA Sulfonate on Pulmonary Hypertension | Pulmonary Hypertension;Pulmonary Arterial Hypertension;Cardiovascular Diseases;Lung Diseases;Tanshinone IIA Sulfonate | Drug: 20 mg sildenafil citrate by mouth;Drug: sodium tanshinone IIA sulfonate diluted with 5% glucose solution,20mg sildenafil citrate by mouth | The First Affiliated Hospital of Guangzhou Medical University | Jiangsu Carefree Pharmaceutical Co., LTD;The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School;Guangdong General Hospital;Sir run run shaw hospital Zhejiang University School of Medicine, Hangzhou, China;The First Affiliated Hospital of Zhengzhou University;Dongguan People's Hospital;Second Affiliated Hospital of Xi'an Jiaotong University;Beijing Chao Yang Hospital;Beijing Anzhen Hospital;Qingdao University | Recruiting | 15 Years | 70 Years | Both | 90 | Phase 2;Phase 3 | China |
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | NCT01953965 (ClinicalTrials.gov) | September 2013 | 26/9/2013 | Look at Way the Heart Functions in People With Pulmonary Hypertension (PH) Who Have Near Normal Right Ventricle (RV) Function and People With Pulmonary Hypertension Who Have Impaired RV Function. Using Imaging Studies PET Scan and Cardiac MRI. | 11C-acetate/18Fluorodeoxyglucose-FDG PET/Cardiac MRI in Pulmonary Hypertension | Pulmonary Arterial Hypertension;Chronic Thromboembolic Pulmonary Hypertension | Drug: 11C-acetate;Drug: [18F]Fluoro-2-deoxy-2-D-glucose;Drug: MultiHance | Brigham and Women's Hospital | University of Pennsylvania;University of Maryland;Yale University | Terminated | 18 Years | 72 Years | Both | 4 | Phase 2 | United States |
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | ChiCTR-TRC-11001321 | 2011-05-01 | 2011-05-01 | Effect of ?-3 Fish Oil Fat on Perioperative Immunity in Patients with Crohn's Disease | Effect of ?-3 Fish Oil Fat on Perioperative Immunity in Patients with Crohn's Disease | Crohn's disease;ICD:K50.9 | control group:Total parenteral nutrition (TPN) will be administrated to patients from day1 to day7 after the operation. Non-protein energy of the TPN is 120kJ/kg/d, of which 60% is supplied by glucose and 40% by fat emulsion. Amino acid of the TPN is 0.8-1.0g/kg/d. Electrolyte, vitamins, trace elements will be added into the TPN. Glucose/insulin ratio is 5:1. In this group, medium-long chain triglyceride will be used.;?-3 Fat group:Total parenteral nutrition (TPN) will be administrated to patients from day1 to day7 after the operation. Non-protein energy of the TPN is 120kJ/kg/d, of which 60% is supplied by glucose and 40% by fat emulsion. Amino acid of the TPN is 0.8-1.0g/kg/d. Electrolyte, vitamins, trace elements will be added into the TPN. Glucose-insulin ratio is 5:1. In this group, medium-long chain triglyceride and ?-3 fish oil fat (Omegaven); | The First Affiliated Hospital of Sun Yat-sen University | NULL | Completed | 14 | 75 | Both | control group:30;?-3 Fat group:30; | China |
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | NCT02383316 (ClinicalTrials.gov) | January 2015 | 23/12/2014 | Study of Metabolic Modifications in Children With Noonan Syndrome | Study of Metabolic Modifications in Children With Noonan Syndrome | Child Syndrome | Other: Oral Glucose tolerance test | University Hospital, Toulouse | NULL | Completed | 7 Years | 18 Years | All | 20 | N/A | France |
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | NCT02383316 (ClinicalTrials.gov) | January 2015 | 23/12/2014 | Study of Metabolic Modifications in Children With Noonan Syndrome | Study of Metabolic Modifications in Children With Noonan Syndrome | Child Syndrome | Other: Oral Glucose tolerance test | University Hospital, Toulouse | NULL | Completed | 7 Years | 18 Years | All | 20 | N/A | France |
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | NCT02180412 (ClinicalTrials.gov) | April 28, 2014 | 25/6/2014 | Controlled Trial of Panhematin in Treatment of Acute Attacks of Porphyria | A Double-blind, Randomized, Placebo-controlled, Parallel Group Trial on the Efficacy and Safety of PanhematinTM in the Treatment of Acute Attacks of Porphyria | Acute Porphyrias | Biological: Panhematin;Other: Glucose | The University of Texas Medical Branch, Galveston | NULL | Active, not recruiting | 18 Years | 100 Years | All | 40 | Phase 2 | United States |
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | NCT04138251 (ClinicalTrials.gov) | June 20, 2019 | 20/6/2019 | Safety, Efficacy Evaluation of Empagliflozin Administration for Neutropenia in Glycogenosis Type 1b and G6PC3 Deficiency | Evaluation of the Safety and Efficacy of Empagliflozin Administration as a Treatment for Neutropenia in Patients With Glycogenosis Type 1b and G6PC3 Deficiency | Glycogen Storage Disease Type I;Glucose 6 Phosphatase Deficiency | Drug: Empagliflozin | Cliniques universitaires Saint-Luc- Université Catholique de Louvain | NULL | Recruiting | 1 Year | 18 Years | All | 5 | Phase 2 | Belgium |
| 2 | NCT03218904 (ClinicalTrials.gov) | March 17, 2017 | 13/7/2017 | Glycogen Storage Disease Breath Test Study | Application of Novel Techniques to Devise Nutritional Therapies in Subjects With Glycogen Storage Disease Type I | Patient Compliance;Healthy | Dietary Supplement: Glucose intake;Dietary Supplement: Carbohydrates intake | University of British Columbia | Saudi Arabian Cultural Bureau, Ottawa;Canadian Institutes of Health Research (CIHR) | Recruiting | 5 Years | 35 Years | All | 38 | N/A | Canada |
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | NCT04599465 (ClinicalTrials.gov) | January 2021 | 21/10/2020 | A Study to Assess the Effect of ELX/TEZ/IVA on Glucose Tolerance in Participants With Cystic Fibrosis (CF) | A Phase 3b Open-label Study to Assess the Effect of Elexacaftor/Tezacaftor/Ivacaftor on Glucose Tolerance in Cystic Fibrosis Subjects With Abnormal Glucose Metabolism | Cystic Fibrosis | Drug: ELX/TEZ/IVA;Drug: IVA | Vertex Pharmaceuticals Incorporated | NULL | Not yet recruiting | 12 Years | N/A | All | 60 | Phase 3 | NULL |
| 2 | EUCTR2020-003170-44-CZ (EUCTR) | 03/12/2020 | 22/10/2020 | A study Evaluating the effect of Elexacaftor/Tezacaftor/Ivacaftor on Glucose Tolerance in Cystic Fibrosis Subjects with Abnormal Glucose Metabolism | A Phase 3b Open-label Study to Assess the Effect of Elexacaftor/Tezacaftor/Ivacaftor on Glucose Tolerance in Cystic Fibrosis Subjects with Abnormal Glucose Metabolism - A Study to Assess the Effect of ELX/TEZ/IVA on Glucose Tolerance in Subjects With Cystic Fibrosis | Cystic Fibrosis MedDRA version: 20.0;Level: PT;Classification code 10011762;Term: Cystic fibrosis;System Organ Class: 10010331 - Congenital, familial and genetic disorders;Therapeutic area: Diseases [C] - Respiratory Tract Diseases [C08] | Product Name: ELX (VX-445)/TEZ (VX-661)/IVA (VX-770) INN or Proposed INN: Elexacaftor INN or Proposed INN: Tezacaftor INN or Proposed INN: IVACAFTOR Trade Name: Ivacaftor Product Name: 150mg IVACAFTOR Product Code: VX-770 INN or Proposed INN: IVACAFTOR | Vertex Pharmaceuticals Incorporated | NULL | Authorised-recruitment may be ongoing or finished | Female: yes Male: yes | 60 | Phase 3 | France;Czech Republic;Spain;Belgium;Australia;Netherlands;Italy | ||
| 3 | NCT04533646 (ClinicalTrials.gov) | December 1, 2020 | 23/8/2020 | Comparison of Meal-Time Dosing of Insulin in Cystic Fibrosis Related Diabetes | Comparison of Meal-Time Dosing of Rapid Acting Insulin Using Carbohydrate Counting vs. Fixed Doses Utilizing Continuous Glucose Monitoring In Patients With Cystic Fibrosis Related Diabetes | Cystic Fibrosis-related Diabetes | Drug: Insulin;Device: Continuous glucose monitor (CGM) | Jagdeesh Ullal | Wake Forest University Health Sciences | Not yet recruiting | 18 Years | 80 Years | All | 20 | Phase 4 | NULL |
| 4 | NCT04579939 (ClinicalTrials.gov) | November 2020 | 29/9/2020 | Oral Glucose Tolerance Testing Using Candy for Cystic Fibrosis | Oral Glucose Tolerance Testing Using Candy: A Sweet Solution to Improve Screening Compliance in Cystic Fibrosis | Cystic Fibrosis | Diagnostic Test: Candy Glucose Tolerance Test | Mayo Clinic | NULL | Not yet recruiting | 10 Years | 21 Years | All | 10 | N/A | United States |
| 5 | NCT03650712 (ClinicalTrials.gov) | July 1, 2019 | 18/7/2018 | EnVision CF Multicenter Study of Glucose Tolerance in Cystic Fibrosis | EnVision CF Multicenter Study of Glucose Tolerance in Cystic Fibrosis | Cystic Fibrosis-related Diabetes | Diagnostic Test: Oral glucose tolerance test;Diagnostic Test: Continuous glucose monitoring;Diagnostic Test: Dexa scan | Katie Larson Ode | NULL | Recruiting | 6 Years | N/A | All | 144 | N/A | United States |
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
| 6 | NCT03961516 (ClinicalTrials.gov) | May 1, 2019 | 16/5/2019 | Glycemic Characterization and Pancreatic Imaging Correlates in Cystic Fibrosis | Glycemic Characterization and Pancreatic Imaging Correlates in Cystic Fibrosis | Cystic Fibrosis;Cystic Fibrosis-related Diabetes;Cystic Fibrosis Liver Disease;Pancreatic Steatosis;Hepatic Steatosis | Device: Frequently Sampled Oral Glucose Tolerance Test and CGM;Radiation: MRI Pancreas and Liver | University Hospitals Cleveland Medical Center | NULL | Recruiting | 6 Years | 40 Years | All | 40 | United States | |
| 7 | NCT02653027 (ClinicalTrials.gov) | January 1, 2018 | 7/1/2016 | Effect of Lumacaftor-ivacaftor on Glucose Handling and Tolerance in Cystic Fibrosis Phe508del | A Study of the Effect of Combination Lumacaftor and Ivacaftor on Glucose Tolerance in Persons With Cystic Fibrosis Who Are Homozygous for the Phe508del Cystic Fibrosis Transmembrane Conductance Regulator Mutation. | Diabetes;Cystic Fibrosis | Drug: Lumacaftor-ivacaftor;Other: OGTT | Massachusetts General Hospital | NULL | Withdrawn | 18 Years | 65 Years | All | 0 | N/A | NULL |
| 8 | NCT02955888 (ClinicalTrials.gov) | January 3, 2017 | 21/10/2016 | Study of Safety, Tolerability & Efficacy in Cystic Fibrosis Patients With Abnormal Glucose Tolerance | A Phase 2, Double-Blind, Placebo Controlled Study to Evaluate the Safety & Tolerability of PBI-4050 and Its Effects on Pancreatic and Pulmonary Function in Cystic Fibrosis Patients With Abnormal Glucose Tolerance | Cystic Fibrosis | Drug: PBI4050;Drug: Placebo | Liminal BioSciences Ltd. | NULL | Terminated | 18 Years | N/A | All | 11 | Phase 2 | Canada |
| 9 | NCT03512119 (ClinicalTrials.gov) | February 11, 2016 | 15/1/2018 | Observational Study of Glucose Tolerance Abnormalities in Patient With Cystic Fibrosis Homozygous for Phe 508 Del CFTR Treated by Lumacaftor-Ivacaftor | Observational Study of Glucose Tolerance Abnormalities in Patient With Cystic Fibrosis Homozygous for Phe 508 Del CFTR Treated by Lumacaftor-Ivacaftor | Cystic Fibrosis Homozygous for Phe 508 Del CFTR;Glucose Intolerance or Newly Diagnosis Diabetes | Drug: Lumacaftor-Ivacaftor treatment | University Hospital, Strasbourg, France | NULL | Completed | 12 Years | N/A | All | 55 | France | |
| 10 | NCT02703155 (ClinicalTrials.gov) | October 2015 | 9/2/2016 | The Use of Home Oral Glucose Tolerance Test Kit in Screening Cystic Fibrosis Related Diabetes | The Use of Self-Administered Electronic Oral Glucose Tolerance Test Kit in Screening Cystic Fibrosis Related Diabetes in Children With Cystic Fibrosis | Cystic Fibrosis Related Diabetes;Cystic Fibrosis | Device: Home Oral Glucose Tolerance Test kit | Great Ormond Street Hospital for Children NHS Foundation Trust | University College, London | Recruiting | 10 Years | 17 Years | Both | 30 | N/A | United Kingdom |
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
| 11 | NCT02569229 (ClinicalTrials.gov) | June 2015 | 12/8/2015 | Glucose Tolerance in Children With Cystic Fibrosis | Glucose Tolerance and Its Clinical Impact in Children and Adolescents With Cystic Fibrosis | Glucose Intolerance;Cystic Fibrosis | Other: Diagnostics for glucose tolerance with 3 different methods. | Christoph Saner | University Hospital Inselspital, Berne | Active, not recruiting | 10 Years | 20 Years | All | 14 | Switzerland | |
| 12 | NCT02398383 (ClinicalTrials.gov) | March 2015 | 22/1/2015 | Role of Glucagon In Glucose Control in Cystic Fibrosis Related Diabetes | Role of Glucagon in Glucose Control in Cystic Fibrosis Related Diabetes | Cystic Fibrosis;Cystic Fibrosis Related Diabetes | Other: Oral Glucose Tolerance Test;Other: Mixed Meal Tolerance Test;Other: Hypoglycemic Clamp | Yale University | NULL | Completed | 12 Years | 45 Years | All | 7 | Early Phase 1 | United States |
| 13 | NCT02202876 (ClinicalTrials.gov) | November 2014 | 25/7/2014 | Redox Imbalance and the Development of Cystic Fibrosis Diabetes | Redox Imbalance and the Development of Cystic Fibrosis Diabetes | Diabetes Mellitus, Type 2;Cystic Fibrosis | Other: Oral Glucose Tolerance Test;Other: High Glycemic Index Meal;Other: Low Glycemic Index Meal;Other: Test Soda;Other: Fruit juice | Emory University | Cystic Fibrosis Foundation | Completed | 1 Year | N/A | All | 34 | N/A | United States |
| 14 | NCT01975259 (ClinicalTrials.gov) | December 2013 | 11/9/2013 | Investigating the Incretin Effect in Cystic Fibrosis | Investigating the Incretin Effect in Cystic Fibrosis | Cystic Fibrosis | Drug: Oral Glucose Tolerance test (75g 2-hour);Drug: Modified Oral Glucose Tolerance Test (50g 4-hours);Drug: Matched isoglycemic clamp;Drug: Hyperglycemic clamp with concurrent GLP-1 infusion;Drug: Hyperglycemic Clamp with concurrent GIP infusion;Drug: Hyperglycemic clamp with placebo infusion;Other: Liquid Meal Test (Carbohydrate-rich);Other: Liquid Meal Test (Fat-rich);Other: Liquid Meal Test (Mixed);Device: Continuous Glucose Monitoring | Liverpool Heart and Chest Hospital NHS Foundation Trust | NULL | Completed | 17 Years | 50 Years | Both | 50 | N/A | United Kingdom |
| 15 | NCT01883037 (ClinicalTrials.gov) | June 2013 | 13/6/2013 | Comparing Laboratory Blood Glucose Results With HemoCue Glucose 201 RT | To Compare the Clinical Accuracy of Glucose Measurement During Oral Glucose Tolerance Test Using Two Methods: i) Laboratory Standard Technique, ii) HemoCue Glucose 201 RT System | Cystic Fibrosis | Other: Blood glucose results | Royal Brompton & Harefield NHS Foundation Trust | NULL | Completed | 16 Years | N/A | Both | 70 | N/A | United Kingdom |
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
| 16 | NCT01852448 (ClinicalTrials.gov) | May 2013 | 9/5/2013 | Genetics of Insulin and Incretins in Cystic Fibrosis | Evaluation of the Enteroinsular Axis in Cystic Fibrosis | Cystic Fibrosis | Genetic: Blood or Saliva Sample Collection;Other: Glucose -potentiated arginine (GPA) stimulation tests | Children's Hospital of Philadelphia | University of Pennsylvania | Active, not recruiting | 2 Years | N/A | All | 350 | United States | |
| 17 | EUCTR2011-002719-27-IT (EUCTR) | 30/12/2011 | 13/03/2012 | EFFECT OF RECOMBINANT HUMAN INSULIN-LIKE GROWTH FACTOR-I ON GLUCOSE TOLERANCE AND AS PREVENTION TOWARDS THE DEVELOPMENT OF CYSTIC FIBROSIS RELATED DIABETES MELLITUS | GLUCOSE METABOLISM AND INFLAMMATORY PARAMETERS UNDER IGF-I TREATMENT IN CYSTIC FIBROSIS - RH-IGF-I IN CYSTIC FIBROSIS | PATIENTS WITH CYSTIC FIBROSIS MedDRA version: 14.1;Level: PT;Classification code 10011766;Term: Cystic fibrosis pancreatic;System Organ Class: 10010331 - Congenital, familial and genetic disorders;Therapeutic area: Diseases [C] - Hormonal diseases [C19] | Trade Name: INCRELEX*SC 1FL 4ML 10MG/ML INN or Proposed INN: MECASERMIN | AZIENDA OSPEDALIERA DI PARMA | NULL | Not Recruiting | Female: yes Male: yes | 20 | Italy | |||
| 18 | NCT03644199 (ClinicalTrials.gov) | March 30, 2011 | 10/5/2016 | Development of Diabetes in Adults With Cystic Fibrosis (CF) | Factors Responsible for the Development of Diabetes in Adults With Cystic Fibrosis | Cystic Fibrosis | Other: Oral Glucose Tolerance Test (OGTT) assessment arm;Other: Mixed meal test evaluation test arm | Liverpool Heart and Chest Hospital NHS Foundation Trust | NULL | Withdrawn | 18 Years | 50 Years | All | 0 | N/A | United Kingdom |
| 19 | NCT01149005 (ClinicalTrials.gov) | June 2010 | 9/6/2010 | Cystic Fibrosis (CF) Exacerbation and Insulin Treatment | Evaluation of Glucose Tolerance and Insulin Treatment in Non Diabetic Patients With Cystic Fibrosis During Acute Pulmonary Exacerbation | Cystic Fibrosis;Impaired Glucose Tolerance;Pulmonary Exacerbation | Drug: novorapid / humalog short acting insulin;Drug: Novo Rapid Insulin (Novonordisk) | Hadassah Medical Organization | NULL | Not yet recruiting | 10 Years | N/A | Both | 30 | N/A | Israel |
| 20 | NCT00967798 (ClinicalTrials.gov) | May 2010 | 27/8/2009 | Prevention of Cystic Fibrosis Diabetes | A Randomized, Double-blind, Placebo-controlled Study to Determine Whether Chronic Treatment of Cystic Fibrosis Subjects With Impaired Glucose Tolerance Using Sitagliptin (Januvia) Prevents the Development of Diabetes | Cystic Fibrosis;Prediabetes | Drug: Sitagliptin | Emory University | NULL | Terminated | 13 Years | N/A | All | 33 | Phase 3 | United States;Canada |
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
| 21 | NCT02723968 (ClinicalTrials.gov) | September 2009 | 21/3/2016 | Cystic Fibrosis Related Diabetes Screening. | Sensitivity and Specificity of Different Methods for Cystic Fibrosis-related Diabetes Screening. | Cystic Fibrosis-related Diabetes | Other: glucose solution at a dose of 1.75 g/kg (up to a maximum of 75 g) for the OGTT and glucose solution at a dose of 0.5 g/kg (up to a maximum of 35 g) was injected in 2.5-3 min for the IGTT;Procedure: HGPIV diagnosis test;Procedure: HOMAR-IR diagnosis test | Hospices Civils de Lyon | NULL | Completed | 10 Years | 18 Years | All | 29 | N/A | NULL |
| 22 | NCT01091025 (ClinicalTrials.gov) | March 2009 | 18/3/2010 | Comparing Two Different Approaches in the Screening of Cystic Fibrosis Related Diabetes | A Comparative Analysis of the Clinical Efficacy of Two Approaches in the Screening for Cystic Fibrosis Related Diabetes in Adult With Cystic Fibrosis: i) a Selective Approach; ii) an Unselected Annual Oral Glucose Tolerance Test | Screening of Cystic Fibrosis Related Diabetes | Other: Glucose profile for 2 weeks | Imperial College London | Royal Brompton & Harefield NHS Foundation Trust | Completed | 16 Years | N/A | All | 100 | N/A | United Kingdom |
| 23 | EUCTR2007-004956-35-GB (EUCTR) | 27/08/2008 | 26/11/2007 | The effect of intensive blood glucose control with insulin on markers of short and medium term outcomes in patients hospitalised with acute exacerbations of chronic lung disease. Pilot Study to test feasibility and safety of a clinical protocol for intensive blood glucose control with insulin on medical wards - Pilot of Intensive Blood Glucose Control with Insulin on Medical Wards | The effect of intensive blood glucose control with insulin on markers of short and medium term outcomes in patients hospitalised with acute exacerbations of chronic lung disease. Pilot Study to test feasibility and safety of a clinical protocol for intensive blood glucose control with insulin on medical wards - Pilot of Intensive Blood Glucose Control with Insulin on Medical Wards | Acute exacerbations of chronic obstructive pulmonary disease. Stress hyperglycaemia. Insulin-induced hypoglycaemia. Cystic fibrosis MedDRA version: 9.1;Level: LLT;Classification code 10010953;Term: COPD exacerbation MedDRA version: 9.1;Classification code 10060439;Term: Stress induced hyperglycaemia MedDRA version: 9.1;Classification code 10022484;Term: Insulin hypoglycaemia MedDRA version: 9.1;Classification code 10011762;Term: Cystic fibrosis | Trade Name: Actrapid 100 IU/ml, Solution for injection in a vial Trade Name: Levemir 100 U/ml solution for injection in a cartridge, Levemir 100 U/ml solution for injection in a pre-filled pen Trade Name: NovoRapid 100 U/ml, solution for injection in a vial. NovoRapid Penfill 100 U/ml, solution for injection in a cartridge. NovoRapid FlexPen 100 U/ml, solution for injection in a pre-filled pen. Trade Name: Lantus® 100 Units/ml solution for injection in a vial. Lantus® 100 Units/ml solution for injection in a cartridge. Lantus® 100 Units/ml solution for injection in a pre-filled pen | St George's, University of London | NULL | Not Recruiting | Female: yes Male: yes | United Kingdom | ||||
| 24 | NCT00476281 (ClinicalTrials.gov) | April 2008 | 18/5/2007 | Nutritional, Metabolic and Respiratory Status in Cystic Fibrosis | Multicenter Prospective Study of Abnormalies Tolerance Glucose by the Continuous Measurement of Glucose of Nutritional Status and Breathing in the Patient With Cystic Fibrosis | Cystic Fibrosis;Diabetes | Procedure: Urinary collect;Procedure: Continuous Glucose Monitoring System (CGMS) | University Hospital, Strasbourg, France | Association d'Aide aux Insuffisants Respiratoires d'Alsace Lorraine | Completed | 10 Years | N/A | All | 114 | N/A | France |
| 25 | EUCTR2005-002997-31-GB (EUCTR) | 10/08/2006 | 09/11/2005 | A multi-centre randomised trial of insulin detemir in pre-diabetes associated with cystic fibrosis. - Randomized trial of insulin detemir in CF associated pre-diabetes | A multi-centre randomised trial of insulin detemir in pre-diabetes associated with cystic fibrosis. - Randomized trial of insulin detemir in CF associated pre-diabetes | Individuals with cystic fibrosis develop diabetes. They exhibit abnormal glucose handling (impaired glucose tolerance), poor growth and a decline in lung function before overt diabetes develops. Early treatment with insulin before diabetes develops may improve weight gain and lung function and delay progression to overt diabetes. | Sheffield Children's NHS Trust | NULL | Not Recruiting | Female: yes Male: yes | 40 | Phase 4 | United Kingdom | |||
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
| 26 | NCT00287443 (ClinicalTrials.gov) | February 2, 2006 | 2/2/2006 | Metabolic Abnormalities in Hispanic Children With Cystic Fibrosis | Cystic Fibrosis | Procedure: Oral Glucose tolerance test;Procedure: Whole body protein turnover;Procedure: IV glucose tolerance test;Procedure: Indirect Calorimetry;Procedure: Dual Energy X-ray Absorptiometry (DEXA);Procedure: Growth Hormone Stimulation Test | University of Texas Southwestern Medical Center | Genentech, Inc. | Withdrawn | 7 Years | 17 Years | All | 0 | N/A | United States | |
| 27 | NCT00287456 (ClinicalTrials.gov) | February 2, 2006 | 2/2/2006 | Use of the Insulin Pump in Cystic Fibrosis Patients With Impaired Glucose Tolerance or CFRD and in Type 1 Diabetes Patients. | Cystic Fibrosis Related Diabetes | Device: Insulin Pump;Drug: Insulin;Procedure: Oral Glucose Tolerance Test;Procedure: Whole body Protein Turnover | University of Texas Southwestern Medical Center | NULL | Withdrawn | 12 Years | 32 Years | All | 0 | N/A | United States | |
| 28 | NCT00483769 (ClinicalTrials.gov) | February 2006 | 6/6/2007 | One Year Glargine Treatment in CFRD Children and Adolescents | One-Year Glargine-Treatment Can Ameliorate Clinical Features in Cystic Fibrosis Children and Adolescents With Glucose Derangements | Cystic Fibrosis;Glucose Metabolism Disorders | Drug: Glargine | Federico II University | NULL | Completed | 3 Years | 20 Years | Both | 20 | Phase 4 | Italy |
| 29 | NCT00687466 (ClinicalTrials.gov) | August 2005 | 27/5/2008 | Study on the Efficacy of Slow Release Insulin in Cystic Fibrosis Patients With Glucide Intolerance and Clinical Decay | Phase 3 Study on the Efficacy of Slow Release Insulin in Cystic Fibrosis Patients With Glucide Intolerance and Clinical Decay | Cystic Fibrosis;Glucose Intolerance | Drug: Insulin | Fondazione per la ricerca sulla Fibrosi Cistica | NULL | Active, not recruiting | 10 Years | 70 Years | Both | 70 | Phase 3 | Italy |
| 30 | EUCTR2005-002135-27-IT (EUCTR) | 06/07/2005 | 28/06/2005 | Glargine insulin efficacy in Cystic Fibrosis patients with glucose intolerance and clinical deterioration | Glargine insulin efficacy in Cystic Fibrosis patients with glucose intolerance and clinical deterioration | Cystic Fibrosis patients with glucose intolerance MedDRA version: 6.1;Level: PT;Classification code 10011762 | Trade Name: LANTUS*SC 5CAR3ML100UI/ML Product Name: NA Product Code: NA INN or Proposed INN: Insulin glargine | ISTITUTO GIANNINA GASLINI | NULL | Not Recruiting | Female: yes Male: yes | Italy | ||||
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
| 31 | EUCTR2004-005019-28-GB (EUCTR) | 09/05/2005 | 19/04/2005 | Diabetes therapy to improve body mass index pulmoanry function in cystic fibrosis subjects with abnormal blood glucose | Diabetes therapy to improve body mass index pulmoanry function in cystic fibrosis subjects with abnormal blood glucose | Cystic fibrosis related diabetes mellitus | Papworth Hospital NHS Foundation Trust | NULL | Not Recruiting | Female: yes Male: yes | 6 | Phase 4 | United Kingdom | |||
| 32 | NCT00014768 (ClinicalTrials.gov) | February 2001 | 10/4/2001 | Study of Metabolic Effects of Pregnancy in Women With Cystic Fibrosis | Cystic Fibrosis | Drug: glucose;Drug: insulin;Drug: leucine | National Center for Research Resources (NCRR) | University of Utah | Terminated | N/A | N/A | Female | 36 | N/A | United States | |
| 33 | EUCTR2020-003170-44-NL (EUCTR) | 09/11/2020 | A study Evaluating the effect of Elexacaftor/Tezacaftor/Ivacaftor on Glucose Tolerance in Cystic Fibrosis Subjects with Abnormal Glucose Metabolism | A Phase 3b Open-label Study to Assess the Effect of Elexacaftor/Tezacaftor/Ivacaftor on Glucose Tolerance in Cystic Fibrosis Subjects with Abnormal Glucose Metabolism - A Study to Assess the Effect of ELX/TEZ/IVA on Glucose Tolerance in Subjects With Cystic Fibrosis | Cystic Fibrosis MedDRA version: 20.0;Level: PT;Classification code 10011762;Term: Cystic fibrosis;System Organ Class: 10010331 - Congenital, familial and genetic disorders;Therapeutic area: Diseases [C] - Respiratory Tract Diseases [C08] | Product Name: ELX (VX-445)/TEZ (VX-661)/IVA (VX-770) INN or Proposed INN: Elexacaftor INN or Proposed INN: Tezacaftor INN or Proposed INN: IVACAFTOR Trade Name: Ivacaftor Product Name: 150mg IVACAFTOR Product Code: VX-770 INN or Proposed INN: IVACAFTOR | Vertex Pharmaceuticals Incorporated | NULL | NA | Female: yes Male: yes | 60 | Phase 3 | France;Czechia;Spain;Belgium;Australia;Netherlands;Italy | |||
| 34 | EUCTR2020-003170-44-FR (EUCTR) | 22/10/2020 | A study Evaluating the effect of Elexacaftor/Tezacaftor/Ivacaftor on Glucose Tolerance in Cystic Fibrosis Subjects with Abnormal Glucose Metabolism | A Phase 3b Open-label Study to Assess the Effect of Elexacaftor/Tezacaftor/Ivacaftor on Glucose Tolerance in Cystic Fibrosis Subjects with Abnormal Glucose Metabolism - A Study to Assess the Effect of ELX/TEZ/IVA on Glucose Tolerance in Subjects With Cystic Fibrosis | Cystic Fibrosis MedDRA version: 20.0;Level: PT;Classification code 10011762;Term: Cystic fibrosis;System Organ Class: 10010331 - Congenital, familial and genetic disorders;Therapeutic area: Diseases [C] - Respiratory Tract Diseases [C08] | Product Name: ELX (VX-445)/TEZ (VX-661)/IVA (VX-770) INN or Proposed INN: Elexacaftor INN or Proposed INN: Tezacaftor INN or Proposed INN: IVACAFTOR Trade Name: Ivacaftor Product Name: 150mg IVACAFTOR Product Code: VX-770 INN or Proposed INN: IVACAFTOR | Vertex Pharmaceuticals Incorporated | NULL | NA | Female: yes Male: yes | 60 | Phase 3 | France;Czech Republic;Spain;Belgium;Australia;Netherlands;Italy | |||
| 35 | EUCTR2020-003170-44-BE (EUCTR) | 16/10/2020 | A study Evaluating the effect of Elexacaftor/Tezacaftor/Ivacaftor on Glucose Tolerance in Cystic Fibrosis Subjects with Abnormal Glucose Metabolism | A Phase 3b Open-label Study to Assess the Effect of Elexacaftor/Tezacaftor/Ivacaftor on Glucose Tolerance in Cystic Fibrosis Subjects with Abnormal Glucose Metabolism - A Study to Assess the Effect of ELX/TEZ/IVA on Glucose Tolerance in Subjects With Cystic Fibrosis | Cystic Fibrosis MedDRA version: 20.0;Level: PT;Classification code 10011762;Term: Cystic fibrosis;System Organ Class: 10010331 - Congenital, familial and genetic disorders;Therapeutic area: Diseases [C] - Respiratory Tract Diseases [C08] | Product Name: ELX (VX-445)/TEZ (VX-661)/IVA (VX-770) INN or Proposed INN: Elexacaftor INN or Proposed INN: Tezacaftor INN or Proposed INN: IVACAFTOR Trade Name: Ivacaftor Product Name: 150mg IVACAFTOR Product Code: VX-770 INN or Proposed INN: IVACAFTOR | Vertex Pharmaceuticals Incorporated | NULL | NA | Female: yes Male: yes | 60 | Phase 3 | France;Czech Republic;Spain;Belgium;Australia;Netherlands;Italy |